Resultats a la cerca d'autor

1

Retrograde Cricopharyngeus Dysfunction, a New Motility Disorder: Single Center Case Series and Treatment Results per Stijn Arnaert, Joris Arts, Karlien Raymenants, Filip Baert, Kathelijne Delsupehe

Publicat 2024

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
2

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice per Cathérine Reenaers, Peter Bossuyt, P. Hindryckx, Hilde Vanpoucke, Anneline Cremer, Filip Baert

Publicat 2018

Obtenir text complet
Revisão

Afegir a favorits

Guardat en:
3

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum per Geert D’Haens, Karel Geboes, Marc Peeters, Filip Baert, Freddy Penninckx, P. Rutgeerts

Publicat 1998

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
4

Clinical Trials in Ulcerative Colitis: A Historical Perspective per Pieter Hindryckx, Filip Baert, Ailsa Hart, Fernando Magro, Alessandro Armuzzi, Laurent Peyrin–Biroulet

Publicat 2015

Obtenir text complet Obtenir text complet
Revisão

Afegir a favorits

Guardat en:
5

Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics per Marc Peeters, Hilde Nevens, Filip Baert, Martin Hiele, A Meyer, Robert Vlietinck, P. Rutgeerts

Publicat 1996

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
6

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease per Séverine Vermeire, M. Noman, Gert Van Assche, Filip Baert, Geert D’Haens, P. Rutgeerts

Publicat 2007

Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
7

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease per Filip Baert, Maja Noman, Séverine Vermeire, Gert Van Assche, Geert D' Haens, An Carbonez, Paul Rutgeerts

Publicat 2003

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
8

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis per Konstantinos Papamichael, Filip Baert, Sophie Tops, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Ann Gils, Marc Ferrante

Publicat 2016

Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
9

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy per Filip Baert, David Drobne, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, S. Lockton, Paul Rutgeerts, Séverine Vermeire

Publicat 2014

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
10

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis per Filip Baert, Niels Vande Casteele, Anita Bengtsson Tops, Maja Noman, Gert Van Assche, P. Rutgeerts, Ann Gils, Séverine Vermeire, Marc Ferrante

Publicat 2014

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
11

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients per Filip Baert, E Glorieus, Cathérine Reenaers, Geert D’Haens, Harald Peeters, D Franchimont, Olivier Dewit, Philippe Caenepeel, Édouard Louis, Gert Van Assche

Publicat 2012

Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
12

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis per Filip Baert, Karel Wouters, Geert D’Haens, P Hoang, Serge Naegels, F D’Heygere, J Holvoet, E Louis, Martine Devos, Karel Geboes

Publicat 1999

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
13

$Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series$

Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series per Marc Ferrante, Geert D’Haens, Olivier Dewit, Filip Baert, Jan Holvoet, Karel Geboes, Gert De Hertogh, Gert Van Assche, Séverine Vermeire, Paul Rutgeerts

Publicat 2009

Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
14

Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial per Geert D’Haens, Sander van Deventer, Ruud van Hogezand, Douglas M. Chalmers, C Kothe, Filip Baert, Tanja Braakman, T Schaible, Karel Geboes, Paul Rutgeerts

Publicat 1999

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
15

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial per Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Filip Baert, Maja Noman, Séverine Vermeire, David Ternant, Hervé Watier, Gilles Paintaud, Paul Rutgeerts

Publicat 2008

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
16

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study per Séverine Vermeire, F D’Heygere, A. Nakad, Denis Franchimont, Fernand Fontaine, Édouard Louis, Philippe Van Hootegem, Olivier Dewit, Guy Lambrecht, Beatrijs Strubbe, Filip Baert

Publicat 2018

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
17

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease per Filip Baert, Liesbeth Moortgat, Gert Van Assche, Philip Caenepeel, Philippe Vergauwe, Martine De Vos, Pieter Stokkers, Daniël W. Hommes, Paul Rutgeerts, Séverine Vermeire, Geert D’Haens

Publicat 2009

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
18

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis per William J. Sandborn, Filip Baert, Silvio Danese, Željko Krznarić, Taku Kobayashi, Xiaopan Yao, Jingjing Chen, Maria Rosario, Siddharth Bhatia, Krisztina Kisfalvi, Geert D’Haens, Séverine Vermeire

Publicat 2019

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
19

Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas per Nancy Van Damme, Philippe Deron, Nadine Van Roy, Pieter Demetter, Alain Bols, Jo Van Dorpe, Filip Baert, Jean–Luc Van Laethem, Frank Speleman, Patrick Pauwels, Marc Peeters

Publicat 2010

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:
20

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease per Geert D’Haens, Marc Ferrante, Séverine Vermeire, Filip Baert, Maja Noman, Liesbeth Moortgat, Patricia Geens, Doreen Iwens, Isolde Aerden, Gert Van Assche, Gust Van Olmen, Paul Rutgeerts

Publicat 2012

Obtenir text complet Obtenir text complet
Artigo

Afegir a favorits

Guardat en:

Resultats de la cerca - Filip Baert

Retrograde Cricopharyngeus Dysfunction, a New Motility Disorder: Single Center Case Series and Treatment Results per Stijn Arnaert, Joris Arts, Karlien Raymenants, Filip Baert, Kathelijne Delsupehe

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice per Cathérine Reenaers, Peter Bossuyt, P. Hindryckx, Hilde Vanpoucke, Anneline Cremer, Filip Baert

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum per Geert D’Haens, Karel Geboes, Marc Peeters, Filip Baert, Freddy Penninckx, P. Rutgeerts

Clinical Trials in Ulcerative Colitis: A Historical Perspective per Pieter Hindryckx, Filip Baert, Ailsa Hart, Fernando Magro, Alessandro Armuzzi, Laurent Peyrin–Biroulet

Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics per Marc Peeters, Hilde Nevens, Filip Baert, Martin Hiele, A Meyer, Robert Vlietinck, P. Rutgeerts

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease per Séverine Vermeire, M. Noman, Gert Van Assche, Filip Baert, Geert D’Haens, P. Rutgeerts

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease per Filip Baert, Maja Noman, Séverine Vermeire, Gert Van Assche, Geert D' Haens, An Carbonez, Paul Rutgeerts

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis per Konstantinos Papamichael, Filip Baert, Sophie Tops, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Ann Gils, Marc Ferrante

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy per Filip Baert, David Drobne, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, S. Lockton, Paul Rutgeerts, Séverine Vermeire

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis per Filip Baert, Niels Vande Casteele, Anita Bengtsson Tops, Maja Noman, Gert Van Assche, P. Rutgeerts, Ann Gils, Séverine Vermeire, Marc Ferrante

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients per Filip Baert, E Glorieus, Cathérine Reenaers, Geert D’Haens, Harald Peeters, D Franchimont, Olivier Dewit, Philippe Caenepeel, Édouard Louis, Gert Van Assche

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis per Filip Baert, Karel Wouters, Geert D’Haens, P Hoang, Serge Naegels, F D’Heygere, J Holvoet, E Louis, Martine Devos, Karel Geboes

Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series per Marc Ferrante, Geert D’Haens, Olivier Dewit, Filip Baert, Jan Holvoet, Karel Geboes, Gert De Hertogh, Gert Van Assche, Séverine Vermeire, Paul Rutgeerts

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial per Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Filip Baert, Maja Noman, Séverine Vermeire, David Ternant, Hervé Watier, Gilles Paintaud, Paul Rutgeerts

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease per Filip Baert, Liesbeth Moortgat, Gert Van Assche, Philip Caenepeel, Philippe Vergauwe, Martine De Vos, Pieter Stokkers, Daniël W. Hommes, Paul Rutgeerts, Séverine Vermeire, Geert D’Haens

Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas per Nancy Van Damme, Philippe Deron, Nadine Van Roy, Pieter Demetter, Alain Bols, Jo Van Dorpe, Filip Baert, Jean–Luc Van Laethem, Frank Speleman, Patrick Pauwels, Marc Peeters

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease per Geert D’Haens, Marc Ferrante, Séverine Vermeire, Filip Baert, Maja Noman, Liesbeth Moortgat, Patricia Geens, Doreen Iwens, Isolde Aerden, Gert Van Assche, Gust Van Olmen, Paul Rutgeerts

Eines de cerca:

Matèries relacionades